BioCentury
ARTICLE | Clinical News

Brincidofovir: Phase II started

October 27, 2014 7:00 AM UTC

Chimerix began an open-label, international Phase II trial to evaluate oral brincidofovir in about 50 patients age >=2 months that test positive for Ebola virus RNA in plasma. Patients enrolled will receive an initial 200 mg dose, followed by 100 mg dose twice weekly for 5 doses. FDA has approved an emergency IND allowing the company to provide brincidofovir to treat Ebola. ...